Date | Price Target | Rating | Analyst |
---|---|---|---|
8/15/2024 | $33.00 | Overweight | Piper Sandler |
12/15/2023 | $25.00 → $15.00 | Buy → Neutral | BofA Securities |
6/30/2023 | $27.00 | Outperform | Wedbush |
2/3/2023 | $17.00 | Outperform | Oppenheimer |
6/23/2022 | $12.00 | Buy | H.C. Wainwright |
3/8/2022 | $31.00 → $27.00 | Hold → Buy | Jefferies |
11/8/2021 | $19.00 → $31.00 | Buy → Hold | Jefferies |
11/8/2021 | Buy → Hold | Jefferies |
Piper Sandler initiated coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00
BofA Securities downgraded Tyra Biosciences from Buy to Neutral and set a new price target of $15.00 from $25.00 previously
Wedbush initiated coverage of Tyra Biosciences with a rating of Outperform and set a new price target of $27.00
10-Q - Tyra Biosciences, Inc. (0001863127) (Filer)
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
3 - Tyra Biosciences, Inc. (0001863127) (Issuer)
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima
-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif., Nov. 29, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the initiation of its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300. TYRA-300, the Company's lead product candidate stemming from its SNÅP platform, is an oral, FGFR3-selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract. "W
CARLSBAD, Calif., Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024 Cantor Global Healthcare Conference. Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, September 17, 2024, at 9:45 am ET. TYRA management will also participate in one-on-one meetings with investors during the conference. A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website
-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif., Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Doug Warner, M.D., as Chief Medical Officer. Dr. Warner will be responsible for overseeing TYRA's clinical portfolio and will serve as a key member of its executive management team. "TYRA is a
- SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - - IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC - - Announced Chief Medical Officer transition plan; search for an external candidate underway with guidance from Science & Technology (S&T) Committee of the Board, including recent additions Dr. Susan Moran and Dr. S. Michael Rothenberg - - Cash, cash equivalents, and marketable securities of $373.8 million at Q2 2024 - CARLSBAD, Calif., Aug. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a cl
-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif., Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Doug Warner, M.D., as Chief Medical Officer. Dr. Warner will be responsible for overseeing TYRA's clinical portfolio and will serve as a key member of its executive management team. "TYRA is a
CARLSBAD, Calif., May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D. The changes are effective immediately. "Susan and Michael's impressive careers will provide TYRA with valuable guidance as we advance our potential next-generation precision candidates toward people in need. We have a unique op
CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead precision medicine program, TYRA-300, for the treatment of achondroplasia. Achondroplasia is the most common form of dwarfism with limited therapeutic options. People living with achondroplasia may experience severe skeletal complications including cranial and spinal stenosis, hydrocephalus and sleep apnea. A s
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
Oppenheimer analyst Matthew Biegler reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $28 price target.
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $28 price target.
SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)